Paul E. Greenberg
Education
M.S., applied microeconomics and finance, MIT Sloan School of Management; M.A., economics, University of Western Ontario; A.B., economics, Vassar College
Summary of Experience
Paul E. Greenberg, Director of Analysis Group’s Health Care Practice, consults to pharmaceutical, biotechnology, and medical device companies in complex business litigation matters. Mr. Greenberg’s litigation experience has included performing economic and statistical analyses in support of testifying experts, as well as presenting findings to investigators from US Attorneys’ Offices and the Office of the Inspector General in numerous cases in which violations of the False Claims Act and/or the Anti-Kickback Statute have been alleged. Mr. Greenberg has provided economic consulting support in connection with class certification, liability, and damages in cases involving allegations of product failure, product fraud, antitrust, and/or patent infringement in the biopharmaceutical industry. He has provided strategic assistance to counsel at various key points in litigation, including pretrial discovery, settlement negotiations, and trial preparation. In the area of health economics and outcomes research (HEOR), Mr. Greenberg has undertaken cost-of-illness studies relating to numerous psychiatric and physical disorders, as well as pharmacoeconomic assessments of the cost-effectiveness of drugs based on data gathered in clinical trials and/or administrative claims files. Mr. Greenberg’s work in HEOR has been widely published in leading medical and health economics journals. He currently serves on the editorial boards of PharmacoEconomics, the Journal of Medical Economics, and Expert Opinion on Pharmacotherapy, and he previously served on the editorial boards of Law360’s Life Sciences and Health Care electronic newsletters.
- Analysis in NFL Players Association Deflategate Matter
- Analyzing Causation and Damages in Data Breach Litigation
- AstraZeneca v. TAP Pharmaceuticals, Inc.
- Comparison of Escitalopram and Citalopram
- Controlled Substance Monitoring and Effective Controls Against Diversion: Investigations and Settlements
- Costs Associated with ADHD Patients and Families
- Economic Burden of Opioid Abuse
- Mylan Pharmaceuticals v. Procter & Gamble Co.
- Pharmaceutical Off-Label Promotion & Kickbacks Settlements
- Quantifying the Economic Burden of Depression
- SmithKline v. Revenue Canada
- Steadfast Insurance Company v. Purdue Frederick Company
- United States of America et al ex rel Brown v Celgene Corp
-
Impact of living with an adult with depressive symptoms among households in the United States
Journal of Affective Disorders, 2024
2024Greenberg P, O'Callaghan L, Fournier AA, Gagnon-Sanschagrin P, Maitland J, Chitnis A
-
The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
Advances in Therapy, 2023
2023Greenberg P, Chitnis A, Louie D, Suthoff E, Chen SY, Maitland J, Gagnon-Sanschagrin P, Fournier AA, Kessler RC
-
Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States
Journal of Clinical Psychiatry, 2022
2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P
-
Health Cos. Can Reduce FCA Risk by Leveraging Data
Law360, 2021
2021Jenny B, Yenikomshian M, Greenberg PE
-
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
PharmacoEconomics, 2021
2021Greenberg P, Fournier A, Sisitsky T, Simes M, Berman R, Koenigsberg S, Kessler R
-
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
PharmacoEconomics (2021) 39:619–625
2021 -
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
Healthcare resource utilization and costs associated with postpartum depression among commercially insured households
Current Medical Research and Opinion, 2020
2020Epperson CN, Huang M, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A
-
US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
PharmacoEconomics - Open, 2020
2020Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P
-
Medicaid spending burden among beneficiaries with treatment-resistant depression
Journal of Comparative Effectiveness Research, February 8, 2019
2019Pilon D, Sheehan J, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE
-
Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges
PharmacoEconomics, March 8, 2019
2019Thesmar D, Sraer D, Pinheiro L, Dadson N, Veliche R, Greenberg PE
-
Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
PLOS One, 2019
2019Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE
-
Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database
Journal of Clinical Psychiatry. Feb 20 2018;79(2)
2018Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE
-
Tracing The Path To Health Care Investigation Settlements
Law 360, April 17, 2017
2017 -
Decision Making in a World of Comparative Effectiveness Research
Book co-edited by Analysis Group
2017 -
Introducing Decision Making in a World of Comparative Effectiveness Research
Decision Making in a World of Comparative Effectiveness Research
2017 -
Perspectives of Comparative Effectiveness Research from the World of Decision Making
Decision Making in a World of Comparative Effectiveness Research
2017 -
Legal Considerations in a World of Comparative Effectiveness Research
Decision Making in a World of Comparative Effectiveness Research
2017Kalb P, Greenberg P, Pike C
-
Viewing Recent Opioid Regulations In Context
Law360, April 1, 2016
2016 -
Can social media data lead to earlier detection of drug-related adverse events
Pharmacoepidemiology and Drug Safety, 2016 Sep 7 doi: 10.1002/pds.4090. [Epub ahead of print]
2016Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.
-
The Growing Economic Burden of Depression in the U.S.
Scientific American MIND Guest Blog, February 25, 2015
2015 -
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
J Clin Psychiatry 2015 Feb;76(2):155-73
2015Greenberg P, Fournier A, Sisitsky T, Pike C, Kessler R
-
What Attorneys Should Know About FDA’s MedWatch Data
Law360, January 29, 2014
2014 -
Big Data Can Yield Big Insights on Promotional Practices
Law360, August 14, 2014
2014 -
Brief of Antitrust Economists as Amici Curiae in Support of Respondents
Amicus Curiae Brief on Reverse Payment Settlements, February 28, 2013
2013Cockburn I, Cremieux P, Grabowski H, Greenberg P, Hubbard R, Hughes J, Snyder E, Stangle B
-
Little Guidance for Lower Courts in FTC v. Actavis
Today's General Council, Aug/Sept 2013, Volume 10/Number 4
2013John L, Leckerman J, Greenberg P
-
Prioritizing Safety Versus Budget: FDA and CMS Adopt Different Stances
FDLI Update, May/June 2012
2012 -
An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low
FDLI Update, January/February 2011
2011Wei E, Claggett B, Greenberg P, Wei LJ
-
Mortality and Nonadherence to AEDS
Sudden Unexpected Death in Epilepsy: Continuing the Global Conversation (Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011)
2011Duh MS, Greenberg PE, Guerin A, Korves C
-
Assessing the Relationship Between Compliance with Antidepressant Therapy and Employer Costs Among Employees in the United States
Journal of Occupational and Environmental Medicine; 52(2) : 115-124. 2010
2010Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux P, Greenberg P
-
Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications
Pain Med. 2010 Nov;11(11):1718-25
2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P
-
Introducing Perspectives on Comparative Effectiveness Research
Pharmacoeconomics. 2010 Oct 1;28(10):787-8. doi: 10.2165/11535820-000000000-00000
2010 -
Perspectives on Comparative Effectiveness Research: Views from Diverse Constituencies
PharmacoEconomics, 2010, vol. 28, issue 10
2010 -
Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance
Depress Anxiety. 2010;27(1):78-89
2010Birnbaum H, Kessler R, Kelley D, Ben-Hamadi R, Joish V, Greenberg P
-
Economic Analysis in Off-Label Promotion Cases
Law360 (published on February 9, 2009)
2009 -
The Growing Role of Economic Analysis in Off-Label Promotion Cases
Rx Compliance Report, Vol. VIII, Issue 8, pp. 7 - 8
2009 -
The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurology
2009Duh M, Paradis P, Latremouille-Viau D, Greenberg P
-
Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants
PharmacoEconomics 2009; 27(6)
2009Birnbaum H, Ben-Hamadi R, Greenberg P, Hsieh M, Tang J, Reygrobellet C
-
Legal and Economic Perspectives Concerning U.S. Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers
PharmacoEconomics, 2009 27 (8)
2009Greenberg P, Kalb P
-
ABA Pharmaceutical Industry Antitrust Handbook
ABA Pharmaceutical Industry Antitrust Handbook
2009Greenberg P, Mishol D, Sisitsky T, Bruno C
-
Antidepressant treatment patterns and costs among US employees
J Med Econ. 2009 Mar;12(1):36-45
2009Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R
-
The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence
Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. Review
2009Duh M, Cahill K, Paradis P, Cremieux P, Greenberg P
-
Treatment persistence, healthcare utilization and costs in adult patients with major depressive disorder: a comparison between escitalopram
J Med Econ. 2009 Jun;12(2):124-35. doi: 10.3111/13696990903093537.
2009Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.
-
Drug Safety and Risk Management Practice: What Drug Companies Can Do
FDLI Update 2008, Issue 3. With Permission from FDLI
2008Duh MS, Greenberg P, Antras L
-
Does Generic Substitution Always Make Sense?
Journal of Medical Economics, Fall 2008
2008 -
Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
PharmacoEconomics 2008;26(2):99-120.
2008Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE
-
Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population
Current Medical Research and Opinion 2008;24(9):2587-2595
2008Wu E, Greenberg P, Yang E, Yu A, Erder M
-
Comparison of treatment persistence, hospital utilization, costs among major depressive disorder geriatric patients treated with escitalopram
Current Medical Research and Opinion 2008;24(10):2805-13
2008Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder M
-
Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication
Archives of General Psychiatry. 2007;64:543-552.
2007Merikangas K, Akiskal H, Angst J, Greenberg P, Hirschfeld R, Petukhova M, Kessler R
-
The Role of Epidemiology in Drug Safety Litigations
FDLI Update 2007, Issue 6. With Permission from FDLI
2007Duh M, Greenberg P, Weiner J
-
Considering the costs of bipolar depression
Behav Healthc 2007 Jan;27(1):45-7
2007Kessler R, Akiskal H, Ames M, Birnbaum H, Greenberg P, Hirschfeld R, Wang P
-
Linking Administrative Claims Data with Archival Productivity Measures To Inform Employer Decision Making
In R Kessler, P Stang (Eds.), Health and Work Productivity: Emerging Issues in Research and Policy. Chicago, IL: University of Chicago Press, Spring 2006
2006 -
A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research
In R Kessler, P Stang (Eds.), Health and Work Productivity: Emerging Issues in Research and Policy. Chicago, IL: University of Chicago Press, Spring 2006
2006 -
Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. Workers
Am J Psychiatry 2006 Sep;163(9):1561-8
2006Kessler R, Akiskal H, Ames M, Birnbaum H, Greenberg P, Robert M, Jin R, Merikangas K, Simon G, Wang P
-
Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001: A Societal Perspective.
Clin J Pain 2006 Oct;22(8):667-76
2006Birnbaum H, White A, Reynolds J, Greenberg P, Zhang M, Vallow S, Schein J, Katz N
-
Off-Label Marketing Investigations in the Pharmaceutical Industry
Analysis Group Forum
2006 -
Roundtable Discussion: Importance of Causation Analysis in Mass Tort Cases
FDLI Update 2006, Issue 6. With Permission from FDLI
2006Greenberg P, Lykos G, Gourley S, Davies C
-
Generic Competition in the U.S. Pharmaceutical Industry
International Journal of the Economics of Business 2006 Feb;13(1):15-38
2006Birnbaum H, Bizan O, Grabowski H, Greenberg P, Saha A
-
Impact and Treatment of Anemia in the Elderly: Clinical, Epidemiological, and Economic Perspectives
Expert Review of Pharmacoeconomics & Outcomes Research
2006Duh M, Latypova A, Greenberg P
-
The Economic Burden of Depression: Societal and Patient Perspectives
Biology of Depression. From Novel Insights to Therapeutic Strategies
2005 -
The economic burden of depression in the US: societal and patient perspectives
Expert Opin Pharmacother 2005 Mar;6(3):369-76
2005 -
Costs of Attention Deficit-Hyperactivity Disorder (ADHD) in the US: Excess Costs of Persons with ADHD and Their Family Members in 2000
Curr Med Res Opin 2005 Feb;21(2):195-206
2005Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR
-
The prevalence and effects of adult attention deficit, hyperactivity disorder on work performance in a nationally representative sample of workers
J Occup Environ Med. 2005 Jun;47(6):565-72
2005Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustün TB.
-
Depression and Fibromyalgia: Treatment and Cost When Diagnosed Separately or Concurrently
J Rheumatol 2004 Aug;31(8):1621-9
2004Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F
-
Economic Implications of Treatment-Resistant Depression Among Employees
Pharmacoeconomics 2004;22(6):363-73
2004Greenberg P, Corey-Lisle P, Birnbaum H, Marynchenko M, Claxton A
-
Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation
FDLI Update 2004, Issue 1. With Permission from FDLI
2004 -
Incidence and Costs of Accidents among Attention-Deficit, Hyperactivity Disorder Patients
J Adolesc Health. 2004 Oct;35(4):346.e1-9.
2004Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.
-
What’s So Different about Anxiety Disorders (such as Phobias)?
Phobias (vol. 7 of the World Psychiatric Association series "Evidence and Experience in Psychiatry"), John Wiley & Sons, Ltd:2004;337-339
2004 -
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
J Clin Psychiatry. 2003 Dec;64(12):1465-75.
2003Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK
-
The Economics of Women and Depression: An Employer Perspective
J Affect Disord. 2003 Mar;74(1):15-22.
2003Birnbaum HG, Leong SA, Greenberg PE
-
Lower Respiratory Tract Infections: Impact on the Workplace
Pharmacoeconomics 2003;21(10):749-59. Erratum in: Pharmacoeconomics 2003;21(12):883
2003Birnbaum H, Morley M, Leong S, Greenberg P, Colice G
-
Economic Cost and Epidemiological Characteristics of Patients with Fibromyalgia Claims
J Rheumatol 2003 Jun;30(6):1318-25
2003Robinson R, Birnbaum H, Morley MA, Sisitsky T, Greenberg P, Claxton A
-
Economic Impact of Olanzapine Plus Fluoxetine Combination Therapy Among Patients Treated for Depression: A Pilot Study
Psychopharmacol Bull. 2003 Summer;37(3):90-8.
2003Corey-Lisle P, Birnbaum H, Greenberg P, Marynchenko M, Dube S
-
The economic burden of depression with painful symptoms
J Clin Psychiatry. 2003;64 Suppl 7:17-23.
2003Greenberg PE, Leong SA, Birnbaum HG, Robinson RL
-
Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis
J Clin Psychiatry. 2003 Oct;64(10):1201-9.
2003Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.
-
Attention-Deficit, Hyperactivity Disorder: Increased Costs for Patients and Their Families
J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1415-23.
2003Swensen AR1, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A
-
Productivity Loss Due to Irritable Bowel Syndrome—Reply
Arch Intern Med. 2003;163(18):2249-2250
2003Greenberg P, Birnbaum H, Leong S, Pike C, Ben-Hamadi R, Barghout V, Frech F, Ofman J
-
The Economic Burden of Anxiety and Stress Disorders
In K Davis (Ed.), Neuropsychopharmacology: The Fifth Generation of Progress. Baltimore, MD: The American College of Neuropsychopharmacology and Lippincott Williams & Wilkins 2002;67:981-92
2002 -
Economic Burden of Respiratory Infections in an Employed Population
Chest 2002 Aug;122(2):603-11
2002Birnbaum H, Morley M, Greenberg P, Colice G
-
Direct and Indirect Costs of Asthma to an Employer
J Allergy Clin Immunol 2002 Feb;109(2):264-70
2002Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.
-
Productivity and Medical Costs of Diabetes in a Large Employer Population
Diabetes Care 2002 Jan;25(1):23-9
2002Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P
-
Identification of a claims data “signature” and economic consequences for treatment-resistant depression
J Clin Psychiatry. 2002 Aug;63(8):717-26.
2002Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.
-
Cost of Depression: Current Assessment and Future Directions
Expert Review of Pharmacoeconomics & Outcomes Research 2001 Oct;1(1):69-76
2001Greenberg P, Leong S, Birnbaum H
-
Assessing the Economic Impact of Psychiatric Disorders: Where to Begin?
Expert Opin Pharmacother. 2001 Apr;2(4):641-52.
2001Greenberg PE, Leong SA, Birnbaum HG
-
The effects of chronic medical conditions on work loss and work cutback
J Occup Environ Med 2001 Mar;43(3):218-25
2001Kessler R, Greenberg P, Mickelson K, Meneades L, Wang P
-
Pharmaceutical Spending and Health Outcomes in the United States
Investing in Health: The Social and Economic Benefits of Healthcare Innovation 2001; 14: 59-76
2001Cremieux P, Ouellette P, Meilleur M, Leong S, Greenberg P, Birnbaum H
-
Identification of Diabetes Patients Using Claims Data: An Economic Analysis
Drug Benefit Trends 2001 Nov;13(suppl B): 28-33
2001Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S
-
Impact of illness and its treatment on workplace costs: regulatory and measurement issues
J Occup Environ Med 2001 Jan;43(1):56-63
2001Greenberg P, Birnbaum H, Kessler R, Morgan M, Stang P
-
Economic burden of pneumonia in an employed population
Arch Intern Med 2001 Dec 10-24;161(22):2725-31
2001Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL
-
Depression and work productivity: the comparative costs of treatment versus nontreatment
J Occup Environ Med 2001 Jan;43(1):2-9
2001Simon G, Barber C, Birnbaum H, Frank R, Greenberg P, Rose R, Wang P, Kessler R
-
Management of Major Depression in the Workplace: Impact on Employee Work Loss
Disease Management & Health Outcomes 2000;7(3):163-71
2000 -
The impact of antidepressant use on social functioning: reboxetine versus fluoxetine
Int Clin Psychopharmacol 2000 Sep;15(5):279-89
2000Venditti L, Arcelus A, Birnbaum H, Greenberg P, Barr C, Rowland C, Williamson T
-
Direct and Indirect Costs of Rheumatoid Arthritis to an Employer
J Occup Environ Med 2000 Jun;42(6):588-96
2000Birnbaum H, Barton M, Greenberg P, Sisitsky T, Auerbach R, Wanke L, Buatti M
-
The Economics of Anxiety Disorders
Psychiatric Times’ Mental Health Economics: Practical Information on Changes in the U.S. Health Care System
2000 -
Savings in Direct Medical Costs from the Use of TOBI™ (Tobramycin Solution for Inhalation) in Patients with Cystic Fibrosis
Clin Ther 2000 Jan;22(1):140-51
2000LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O
-
The economic burden of anxiety disorders in the 1990s
J Clin Psychiatry 1999 Jul;60(7):427-35
1999Greenberg P, Sisitsky T, Kessler R, Finkelstein S, Berndt E, Davidson J, Ballenger J, Fyer A
-
Using healthcare claims data for outcomes research and pharmacoeconomic analyses
Pharmacoeconomics 1999 Jul;16(1):1-8
1999Birnbaum H, Cremieux P, Greenberg P, LeLorier J, Ostrander J, Venditti L
-
Pharmacoeconomics and health policy: Current applications and prospects for the future
Pharmacoeconomics 1999 Nov;16(5 Pt 1):425-32
1999Greenberg P, Arcelus A, Birnbaum H, Cremieux P, LeLorier J, Ouellette P, Slavin M
-
Depression in the workplace: effects on short-term disability
Health Aff 1999 Sep-Oct;18(5):163-71
1999Kessler R, Barber C, Birnbaum H, Frank R, Greenberg P, Rose R, Simon G, Wang P
-
Workplace Burden of Depression: Case Study in Social Functioning Using Employer Claims Data
Drug Benefit Trends 1999; 11 (8): 6-12
1999Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T
-
Workplace performance effects from chronic depression and its treatment
J Health Econ 1998 Oct;17(5):511-35
1998Berndt E, Finkelstein S, Greenberg P, Howland R, Keith A, Rush A, Russell J, Keller M
-
The Next Phase of Managed Care: Targeting Investments in Employee Health
On Managed Care 1997 Sept
1997Greenberg P, Berndt E, Finkelstein S
-
Price Growth of prescription pharmaceutical preparations: an update and extension.
Competitive Strategies in the Pharmaceutical Industry
1996Berndt E, Greenberg P
-
How Much Does Depression Cost Society?
The Harvard Mental Health Letter
1996Greenberg P, Finkelstein S
-
Depression in the Workplace: An Economic Perspective
Selective Serotonin Re-Uptake Inhibitors
1996Greenberg P, Kessler R, Nells T, Finkelstein S, Berndt E
-
Improvement in subjective work performance after treatment of chronic depression: some preliminary results
Chronic Depression Study Group. Psychopharmacol Bull 1996;32(1):33-40
1996Finkelstein S, Berndt E, Greenberg P, Parsley R, Russell J, Keller M
-
Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry
The National Law Journal 1995 Sept.
1995Danzon P, Stamm L, Greenberg P
-
Economic consequences of illness in the workplace
Sloan Management Review 1995 Summer
1995Greenberg P, Finkelstein S, Berndt E
-
Calculating the workplace cost of chronic disease
Bus Health 1995 Sep;13(9):27-8
1995Greenberg P, Finkelstein S, Berndt E
-
Consolidation and Restructuring: The Next Step in Managed Care
Health Care Manag 1995 Oct;2(1):221-35
1995Greenberg P, Danzon P, Stamm L
-
The Economic Burden of Depression in 1990
Journal of Clinical Psychiatry 1993 Nov.
1993Greenberg P, Stiglin L, Finkelstein S, Berndt E
-
Depression: a Neglected Major Illness
J Clin Psychiatry 1993 Nov;54(11):419-24
1993Greenberg P, Stiglin L, Finkelstein S, Berndt E
-
April 12, 2022
-
June 14, 2021
-
June 7, 2021
-
May 5, 2021
-
March 16, 2021